Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Management to host conference call and webcast on Wednesday, May 27, 2015 at 5:00 p.m. EDT.
Alzheimer's Assoc. 4h4 hours ago
Discusses toll Alzheimer's will take on U.S. economy w/out more research funding. #NIHCaucus #ENDALZ
Click here : Alzheimer's Association
Marcum Microcap Conference Presentation on May 28, 2015, at 2:30 p.m. EDT / 11:30 a.m. PDT-
2 Conferences on May 28, 2015: 2015 Marcum Microcap Conference and SEETHRUEQUITY 4TH ANNUAL MICROCAP INVESTOR CONFERENCE
Yes I agree! Also partnerships would be nice.
It should go more than 6 cents today. GLTA!
"Advancing MANF, our first internally-discovered therapeutic product candidate, into human clinical studies will be a major advancement for the Company. Rapid production of MANF in collaboration with Catalent will enable us to achieve this objective as quickly and in the most cost-effective manner possible. The Company is currently targeting the orphan ocular indication retinitis pigmentosa (RP) for first-in-man studies, expected to start in 2016.
The project will utilize Catalent's proprietary GPEx® technology, which creates high-expression, extremely stable cell lines with speed and efficiency, typically capable of getting drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx® technology span from early feasibility studies, to clinical manufacturing and commercial scale production.
About Catalent:
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
AMBS is moving forward in growth mode. They are currently undervalued.
Thanks for letting me know.
My Pick $AMBS
My 2nd choice $TTNP
Two Conferences:
SEETHRUEQUITY 4TH ANNUAL MICROCAP INVESTOR CONFERENCE New York City on May 28, 2015 8am - 6pm
AAIC>.15 Alzheimer's Association International Conference July 18-23, 2015 - Washington, D.C. United States
Yes, I agree! Wow! Alzheimer's Association International Conference! Sounds Good!
Those aren't duplicates. A duplicate will be within seconds of the original post. Moderator is not allowed to delete them.
Dominion Capital LLC --- 25,764,178 Shares--- 04/11/2014
REGENT INVESTMENT MANAGEMENT LLC --- 270,746 Shares --- 03/31/2015
Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
I totally agree! Many long-term shareholders are tired of waiting. MANF is going to be huge! Also LymPro, Eltoprazine and MSPrecise.
Tomorrow, we should get more information from AMBS.
The Man ?@nomorefor 7h7 hours ago
@G_Commish good evening, will $ambs have any presence at AAN in Wash DC?
Gerald Commissiong ?@G_Commish 7h7 hours ago
@nomorefor Yes, the MSPrecise investigator meeting is there, and our AMDX Bus Dev head and CDO will be attending the Alzheimer's sessions.
Thanks jeffshir, sounds good!
Never know what will happen. It can move up high or down low. We can guess. Nothing wrong with that.
You never know, it could happen.
Sludge Reports ?@SludgeReports 3h3 hours ago
@JNapodano It was? Oh you mean the 'designation' which means simple paperwork was filed. Not approved per FDA site. $AMBS
Sludge Reports ?@SludgeReports 3h3 hours ago
@JNapodano Here ya go Jason, so you can track it correctly. www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=457514 … $AMBS
Jason Napodano, CFA ?@JNapodano 3h3 hours ago
@sludgereports EMA gave positive thumbs up, but final decision from EC still to come. Looks like just a formality (paperwork).
Sludge Reports ?@SludgeReports 3h3 hours ago
@JNapodano Yep! But that's the same as the FDA designation isn't it? Now they can proceed with trials and stuff? Good news.
slurrpie123 ?@slurrpie123 7h7 hours ago
@G_Commish What are your thoughts on Jason's assessment on where things stand currently?
keith hoffman ?@kent8692 7h7 hours ago
@slurrpie123 @G_Commish @JNapodano I don't think Jason could have been more correct, and so $AMBS continues to spiral down into oblivion.
Jason Napodano, CFA ?@JNapodano 7h7 hours ago
@kent8692 @slurrpie123 @g_commish Everything I noted in there is easily fixable. Nothing is fundamental. Positive data changes everything!
keith hoffman ?@kent8692 7h7 hours ago
@JNapodano @slurrpie123 @G_Commish Agreed, but question remains....When? Not trying to bash (hell, I'm long), but their reality isn't pretty
Jason Napodano, CFA ?@JNapodano 7h7 hours ago
@kent8692 @slurrpie123 @g_commish Like Tom Petty said - The waiting is the hardest part. Do do do doo la laaa.
The Man ?@nomorefor 7h7 hours ago
@JNapodano thanks JN. Many here will focus on the negative. Waiting has never been my strength, but I'm here to stay. $ambs
Daniel Pinsky ?@pinsky6 Mar 30
Your investors are looking for answers!!!!
Gerald Commissiong ?@G_Commish 1h1 hour ago
What is a phase 2b PD + a unique orphan ophthal + a unique Dx pipeline + an option on ph 2 ultra
orphan derisked asset worth?
Daniel Pinsky ?@pinsky6 1h1 hour ago
I'm not doubting significant worth and assets, but the cont. increase in shares + lack of foreseeable rev is making me nervous!!
Gerald Commissiong ?@G_Commish 59m59 minutes ago
Every great biotech goes through challenges in the market. Getting past them demonstrates the resilience required to succeed.
Daniel Pinsky ?@pinsky6 19m19 minutes ago
Can we get some clearer guidance on potential revenue and lympro silence?
Gerald Commissiong ?@G_Commish 9m9 minutes ago
On sens spec data. We control lympro, exosome, lipids and proteins in AD blood tests. Who else has that?
Daniel Pinsky ?@pinsky6 5m5 minutes ago
Best of luck to you and your team, I hope what you have responded with can be capitalized on before terminal dilution occurs!!!!
Scott Glibowski ?@ScottGlibowski 5m5 minutes ago
I think that is awesome!! But the market wants guidance and to see customers especially BP 2 verify it is real deal
Help for Alzheimer's sufferers!
Alzheimer’s breakthrough uses ultrasound technology
That is so good to know there are cures for Alzheimer's disease!
(PPJE) PPJ Healthcare Enterprises Inc had 1:100 R/S on Dec. 1, 2014, 1:100 R/S on Oct. 26, 2011 and 1:400 R/S on April 24, 2008
PPJE R/S:
1:100 R/S on Dec. 1, 2014
1:100 R/S on Oct. 26, 2011
1:400 R/S on April 24, 2008
If you know any upcoming r/s, let us know.
(AXMM) Axiom/Paper Nuts - Pump and Dump Scam
I am very disappointed in what is going on. So sad that we can't trust CEO. But I still believe in LymPro and etc. Just have to be patience.
Jason Napodano, 43m43 minutes ago
@stockandstuff @vichristi Raising through LPC.
Jason Napodano, 6m6 minutes ago
@vichristi Not a lot to say right now. They will file 10K shortly and host a call. What is there to say before then?
I hope the 10K is about AMBS revenue!
(PSID) PositiveID Corp. had 1:25 R/S on Apr. 23, 2013 - Pump and Dump Scam!